These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 34780933)

  • 21. Albumin-Based Nitric Oxide Traffic System for the Treatment of Intractable Cancers.
    Ishima Y
    Biol Pharm Bull; 2017; 40(2):128-134. PubMed ID: 28154250
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GA/GB fold switching may modulate fatty acid transfer from human serum albumin to bacteria.
    Polticelli F; Caprari S; Gianni S; Ascenzi P
    IUBMB Life; 2012 Nov; 64(11):885-8. PubMed ID: 23086813
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long chain fatty acids alter the interactive binding of ligands to the two principal drug binding sites of human serum albumin.
    Yamasaki K; Hyodo S; Taguchi K; Nishi K; Yamaotsu N; Hirono S; Chuang VTG; Seo H; Maruyama T; Otagiri M
    PLoS One; 2017; 12(6):e0180404. PubMed ID: 28662200
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A molecular mechanism for modulating plasma Zn speciation by fatty acids.
    Lu J; Stewart AJ; Sleep D; Sadler PJ; Pinheiro TJ; Blindauer CA
    J Am Chem Soc; 2012 Jan; 134(3):1454-7. PubMed ID: 22239162
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chromatographic analysis of the effects of fatty acids and glycation on binding by probes for Sudlow sites I and II to human serum albumin.
    Anguizola J; Debolt E; Suresh D; Hage DS
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 May; 1021():175-181. PubMed ID: 26468085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Uniqueness of Albumin as a Carrier in Nanodrug Delivery.
    Spada A; Emami J; Tuszynski JA; Lavasanifar A
    Mol Pharm; 2021 May; 18(5):1862-1894. PubMed ID: 33787270
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Endogenous metabolites as modulators of the transport of drugs by serum albumin].
    Bender KI; Lutsevich NF; Lutsevich AN; Kupchikov VV
    Farmakol Toksikol; 1990; 53(3):72-80. PubMed ID: 2201566
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Studies on drug-human serum albumin binding: the current state of the matter.
    Zhivkova ZD
    Curr Pharm Des; 2015; 21(14):1817-30. PubMed ID: 25732557
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Paclitaxel binding to the fatty acid-induced conformation of human serum albumin--automated docking studies.
    Paal K; Shkarupin A
    Bioorg Med Chem; 2007 Dec; 15(24):7568-75. PubMed ID: 17892938
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of interactions between platinum-/ruthenium-based anticancer agents and human serum albumin: development of HSA carrier for metal-based drugs.
    Gou Y; Zhang Y; Yang F; Liang H
    Curr Pharm Des; 2015; 21(14):1848-61. PubMed ID: 25732554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fatty acids influence binding of cobalt to serum albumin in patients with fatty liver.
    Amirtharaj GJ; Natarajan SK; Mukhopadhya A; Zachariah UG; Hegde SK; Kurian G; Balasubramanian KA; Ramachandran A
    Biochim Biophys Acta; 2008 May; 1782(5):349-54. PubMed ID: 18346470
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heat-induced conformational unfolding of fatty acid-free and fatted camel serum albumin: a comparative study.
    Farivar F; Moosavi-Movahedi AA; Salami M; Bohlooli M; Niasari-Naslaji A
    Cell Biochem Biophys; 2013 Nov; 67(2):727-34. PubMed ID: 23512227
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum albumin as a local therapeutic agent in cell therapy and tissue engineering.
    Horváthy DB; Simon M; Schwarz CM; Masteling M; Vácz G; Hornyák I; Lacza Z
    Biofactors; 2017 May; 43(3):315-330. PubMed ID: 27859738
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structure and ligand binding properties of human serum albumin.
    Kragh-Hansen U
    Dan Med Bull; 1990 Feb; 37(1):57-84. PubMed ID: 2155760
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interactive associations of drug-drug and drug-drug-drug with IIA subdomain of human serum albumin.
    Yang F; Yue J; Ma L; Ma Z; Li M; Wu X; Liang H
    Mol Pharm; 2012 Nov; 9(11):3259-65. PubMed ID: 23009653
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ligand-binding properties of albumin Parklands: Asp365----His.
    Reed RG
    Biochim Biophys Acta; 1988 May; 965(2-3):114-7. PubMed ID: 3365447
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Displacement by anionic drugs of endogenous ligands bound to albumin in uremic serum.
    Mabuchi H; Nakahashi H
    Ther Drug Monit; 1988; 10(3):261-4. PubMed ID: 3140432
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Practical aspects of the ligand-binding and enzymatic properties of human serum albumin.
    Kragh-Hansen U; Chuang VT; Otagiri M
    Biol Pharm Bull; 2002 Jun; 25(6):695-704. PubMed ID: 12081132
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A metalloproteomic analysis of interactions between plasma proteins and zinc: elevated fatty acid levels affect zinc distribution.
    Coverdale JPC; Barnett JP; Adamu AH; Griffiths EJ; Stewart AJ; Blindauer CA
    Metallomics; 2019 Nov; 11(11):1805-1819. PubMed ID: 31612889
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regulation of amantadine hydrochloride binding with IIA subdomain of human serum albumin by fatty acid chains.
    Yang F; Lee P; Ma Z; Ma L; Yang G; Wu X; Liang H
    J Pharm Sci; 2013 Jan; 102(1):84-92. PubMed ID: 23108589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.